Cis-Diamminedichloroplatinum Ii
Invasive Ductal Breast Carcinoma
Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
RenJi Hospital
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03201861CT.gov Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women | — | Recruiting | — | — | — |
NCT02221999CT.gov Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Invasive Ductal Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cis-Diamminedichloroplatinum Ii (this asset) | RenJi Hospital | P3 | BB · 68 |
| Carboplatin | GBG Forschungs GmbH | P3 | BBB |
| Letrozole | University of Washington | P4 | BBB |
| Cyclophosphamide | UMC Utrecht | P3 | BB |
| Pertuzumab | GBG Forschungs GmbH | P3 | BB |
| Trastuzumab | GBG Forschungs GmbH | P3 | BB |
| Epirubicin | GBG Forschungs GmbH | P3 | BB |
| Fulvestrant | G1 Therapeutics, Inc. | P3 | BB |
| Adriamycin | GBG Forschungs GmbH | P3 | BB |
+27 more in the Invasive Ductal Breast Carcinoma cohort
Other indications for Cis-Diamminedichloroplatinum Ii
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Squamous Cell Lung Carcinoma | — | P4 | BBB · 78 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 77 |
| Adenocarcinoma | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Cis-Diamminedichloroplatinum Ii in Invasive Ductal Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/cis-diamminedichloroplatinum-ii-invasive-ductal-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →